Trial Profile
A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinoma and (in selected centres) MRI and FDG-PET/CT Sub-studies
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 28 Dec 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Lapatinib (Primary) ; Capecitabine; Cisplatin; Epirubicin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ST03
- 20 Dec 2023 Results deriving tissue sections from this and other study to assess clinical utility of the SARIFA status in oesophagogastric cancer patients treated with perioperative chemotherapy , published in the British Journal of Cancer
- 03 Apr 2022 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 27 Jul 2020 This trial is discontinued in UK (Global End Date: 30 Nov 2018), according to European Clinical Trials Database record.